COVID-19 drug price deemed 'reasonable'

Gilead Sciences announced pricing for the first drug authorized to treat COVID-19 in the United States, and industry observers did not immediately pass out from sticker shock. The price range for the drug remdesivir — $3,120 for commercially insured U.S. patients, and $2,340 for government programs here and abroad — was in the neighborhood of the pricing suggestions announced previously by the independent Institute for Clinical and Economic Review (ICER) in Boston.